CancerDrs

Head and Neck Cancer clinical trials in Maryland

35 actively recruiting head and neck cancer trials at 6 sites across Maryland.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…

Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in Maryland:
  • Site #0112 — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Maryland:
  • University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Maryland:
  • University of Maryland — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Background: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with…

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT07444723
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Maryland:
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Greater Baltimore Medical Center — Baltimore, Maryland
  • Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
  • UM Upper Chesapeake Medical Center — Bel Air, Maryland
  • Suburban Hospital — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Maryland:
  • Maryland Proton Treatment Center — Baltimore, Maryland
  • University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
  • Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
  • UM Baltimore Washington Medical Center/Tate Cancer Center — Glen Burnie, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Maryland:
  • Local Institution - 2133 — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Maryland:
  • University of Maryland School of Medicine — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Maryland:
  • National Institutes of Health — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Maryland:
  • Johns Hopkins University — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds…

Sponsor: University of Maryland, Baltimore
NCT ID: NCT06088381
Sites in Maryland:
  • Maryland Proton Treatment Center — Baltimore, Maryland
  • University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
  • Upper Chesapeake Health — Bel Air, Maryland
  • Central Maryland Radiation Oncology — Columbia, Maryland
  • Baltimore Washington Medical Center — Glen Burnie, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…

Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Study rationale High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation. There are two methods of TSH stimulation endogenous by thyroid hormone withdrawal (…

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT03841617
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Background: Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with certain types of HNSCC survive for 5 years. Objective: To test a new drug treatme…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161545
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can be…

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT04927416
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Maryland:
  • Exelixis Clinical Site #14 — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…

Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in Maryland:
  • Johns Hopkins Hospital /ID# 254056 — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Research…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06479811
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

The goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well differentiated thyroid cancers (DTC) with iodine-avid metastases. Th…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04892303
Sites in Maryland:
  • The Johns Hopkins SKCCC — Baltimore, Maryland
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in Maryland. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07